We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that the FDA accepted the company’s new drug application (“NDA”) for its isocitrate dehydrogenase 1 (IDH1) mutant inhibitor ivosidenib (AG-120). The company is seeking to get ivosidenib approved for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (“AML”) with an IDH1 mutation. The FDA granted priority review to the candidate and set an action date of Aug 21, 2018.
Year to date, Agios’ share price improved 58.2%, compared with the industry’s gain of 16.8%.
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Ivosidenib is being evaluated in a phase I expansion cohort for treatment of patients with IDH1m R/R AML. Data from the study demonstrated durable responses in patients with the given indication. This enabled the company to submit a NDA to the FDA for ivosidenib in December 2017.
In addition to the NDA, a premarket approval application was also submitted to the FDA by Abbott Laboratories (ABT - Free Report) for the FDA review of an IDH1 assay on the Abbott m2000 RealTime System. The assay automatically prepares samples and analyzes batches for nucleic acid amplification and detection. IDH1 mutations occur in about 6% to 10% of AML patients. The Abbott assay will serve as a companion diagnostic for ivosidenib.
Ivosidenib is also being evaluated in phase I study for treatment of advanced hematologic malignancies and phase I/II combination with Celgene’s Vidaza for treatment of newly diagnosed AML patients, who are not eligible for intensive chemotherapy.
The potential approval of the candidate will boost sales for the company.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days. The company pulled off a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 416.1% over a year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Image: Bigstock
FDA Grants Agios' (AGIO) Leukemia Candidate Priority Review
Agios Pharmaceuticals, Inc. (AGIO - Free Report) announced that the FDA accepted the company’s new drug application (“NDA”) for its isocitrate dehydrogenase 1 (IDH1) mutant inhibitor ivosidenib (AG-120). The company is seeking to get ivosidenib approved for the treatment of patients with relapsed or refractory (R/R) acute myeloid leukemia (“AML”) with an IDH1 mutation. The FDA granted priority review to the candidate and set an action date of Aug 21, 2018.
Year to date, Agios’ share price improved 58.2%, compared with the industry’s gain of 16.8%.
Priority Review designation from the FDA is generally granted to drugs that have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.
Ivosidenib is being evaluated in a phase I expansion cohort for treatment of patients with IDH1m R/R AML. Data from the study demonstrated durable responses in patients with the given indication. This enabled the company to submit a NDA to the FDA for ivosidenib in December 2017.
In addition to the NDA, a premarket approval application was also submitted to the FDA by Abbott Laboratories (ABT - Free Report) for the FDA review of an IDH1 assay on the Abbott m2000 RealTime System. The assay automatically prepares samples and analyzes batches for nucleic acid amplification and detection. IDH1 mutations occur in about 6% to 10% of AML patients. The Abbott assay will serve as a companion diagnostic for ivosidenib.
Ivosidenib is also being evaluated in phase I study for treatment of advanced hematologic malignancies and phase I/II combination with Celgene’s Vidaza for treatment of newly diagnosed AML patients, who are not eligible for intensive chemotherapy.
The potential approval of the candidate will boost sales for the company.
Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. Price | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Stock to Consider
Agios is a Zacks Rank #3 (Hold) stock.
A better-ranked stock from the health care space is XOMA Corp (XOMA - Free Report) carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
XOMA’s loss per share estimates have narrowed from 99 cents to 42 cents for 2018 in the last 60 days. The company pulled off a positive earnings surprise in one of the last four quarters, with an average beat of 47.92%. Share price of the company skyrocketed 416.1% over a year.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>